The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. We developed a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in humans. Read full article in Science (Science, 2001) and a WT1 vaccine, also in national trials (Blood, 2010.)
We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013,) as well as prototype targeted nano-machines (Nature Nano, 2013).
David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics
Research FocusMolecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
EducationMD, PhD, Johns Hopkins University School of Medicine
- Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Whitten J, Tan T, Liu H, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C and Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.
- McDevitt MR, Ma, DS, Lai LT, Simon J, Frank RK, Borchardt P, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators. Science. 2001 Nov 16;294(5546):1537-40.